When juxtaposed with both non-Hispanic White and other Asian subgroups, Japanese patients still demonstrated the highest rate of non-metastatic and node-negative disease, the lowest rate of HER2+ disease, the highest 10-year cancer-specific survival rate, and the highest proportion of being insured, thus better access to healthcare [18]. This evidence concerns the gene ERBB2 and cancer.